BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27069189)

  • 1. Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D; Karlikova M; Svobodova J
    Anticancer Res; 2016 Apr; 36(4):1973-8. PubMed ID: 27069189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis.
    Windrichova J; Kucera R; Fuchsova R; Topolcan O; Fiala O; Svobodova J; Finek J; Slipkova D
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818807466. PubMed ID: 30343636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D
    Anticancer Res; 2017 Mar; 37(3):1501-1505. PubMed ID: 28314325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
    Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
    Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone remodeling markers in the detection of bone metastases in prostate cancer.
    de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
    Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
    Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
    Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
    Johansen JS; Brasso K; Iversen P; Teisner B; Garnero P; Price PA; Christensen IJ
    Clin Cancer Res; 2007 Jun; 13(11):3244-9. PubMed ID: 17545529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TARTRAT-RESISTANT ACID PHOSPHATASE AS BONE'S RESORBTION MARKER IN PATIENTS WITH BONE METASTASES].
    Dedkov AG; Boychuk SI; Stakhovsky EA; Kukushkina MN; Kovalchuk PA
    Lik Sprava; 2015; (5-6):104-9. PubMed ID: 27089726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
    Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
    Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
    Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
    Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.